← Back to Clinical Trials
Recruiting NCT04190602

NCT04190602 Multicenter Post-Market Observational Registry of the NeoChord Artificial Chordae Delivery System

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT04190602
Status Recruiting
Phase
Sponsor NeoChord
Condition Mitral Regurgitation
Study Type OBSERVATIONAL
Enrollment 500 participants
Start Date 2020-02-09
Primary Completion 2022-10

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL
Interventions
NeoChord Artificial Chordae Delivery System, Model DS1000

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 500 participants in total. It began in 2020-02-09 with a primary completion date of 2022-10.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The objective of this study is to evaluate the 5-year outcomes of participants with degenerative mitral valve disease treated with the NeoChord Artificial Chordae System, Model DS1000 in a post-market setting.

Eligibility Criteria

Inclusion Criteria: * Has Grade III Moderate or Grade IV Severe degenerative or mixed disease mitral valve regurgitation * Study procedure completed after 31 December 2016 Exclusion Criteria: * Heavily calcified valves * Valvular retraction with severely reduced mobility * Active bacterial endocarditis * Complex mechanism of MR (leaflet perforation, etc.) * Significant tethering of leaflets * Inflammatory valve disease

Contact & Investigator

Central Contact

Alexandar Jonkers

✉ ajonkers@neochord.com

📞 +31 610740977

Principal Investigator

Andres Beiras Fernandez, MD PhD

PRINCIPAL INVESTIGATOR

Johannes Gutenberg University Mainz

Frequently Asked Questions

Who can join the NCT04190602 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Mitral Regurgitation. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT04190602 currently recruiting?

Yes, NCT04190602 is actively recruiting participants. Contact the research team at ajonkers@neochord.com for enrollment information.

Where is the NCT04190602 trial being conducted?

This trial is being conducted at Bonn, Germany, Frankfurt, Germany, Mainz, Germany, Athens, Greece and 1 additional location.

Who is sponsoring the NCT04190602 clinical trial?

NCT04190602 is sponsored by NeoChord. The principal investigator is Andres Beiras Fernandez, MD PhD at Johannes Gutenberg University Mainz. The trial plans to enroll 500 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology